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Abstract
Background: Enterococci have emerged as a significant cause of nosocomial infections in many
parts of the world over the last decade. The most common enterococci strains present in clinical
isolates are E. faecalis and  E. faecium which have acquired resistant to either gentamicin or
vancomycin. The conventional culture test takes 2–5 days to yield complete information of the
organism and its antibiotic sensitivity pattern. Hence our present study was focused on developing
a nanoplex PCR assay for the rapid detection of vancomycin and bifunctional aminoglycoside
resistant enterococci (V-BiA-RE). This assay simultaneously detects 8 genes namely 16S rRNA of
Enterococcus genus, ddl of E. faecalis and E. faecium, aacA-aphD that encodes high level gentamicin
resistance (HLGR), multilevel vancomycin resistant genotypes such as vanA, vanB, vanC and vanD
and one internal control gene.
Results: Unique and specific primer pairs were designed to amplify the 8 genes. The specificity of
the primers was confirmed by DNA sequencing of the nanoplex PCR products and BLAST analysis.
The sensitivity and specificity of V-BiA-RE nanoplex PCR assay was evaluated against the
conventional culture method. The analytical sensitivity of the assay was found to be 1 ng at the
DNA level while the analytical specificity was evaluated with 43 reference enterococci and non-
enterococcal strains and was found to be 100%. The diagnostic accuracy was determined using 159
clinical specimens, which showed that 97% of the clinical isolates belonged to E. faecalis, of which
26% showed the HLGR genotype, but none were vancomycin resistant. The presence of an internal
control in the V-BiA-RE nanoplex PCR assay helped us to rule out false negative cases.
Conclusion: The nanoplex PCR assay is robust and can give results within 4 hours about the 8
genes that are essential for the identification of the most common Enterococcus spp. and their
antibiotic sensitivity pattern. The PCR assay developed in this study can be used as an effective
surveillance tool to study the prevalence of enterococci and their antibiotic resistance pattern in
hospitals and farm animals.
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Background
Enterococci have emerged as prominent nosocomial
pathogens that cause a variety of clinical infections. Ente-
rococcus faecalis and Enterococcus faecium are clinically sig-
nificant species that are implicated in 90% and 5–10% of
enterococcal infections, respectively [1].
The widespread use and misuse of antimicrobials such as
glycopeptides and aminoglycosides in human and live-
stock have resulted in the rapid increase of vancomycin
and high level gentamicin-resistance in Enterococcus
strains [2]. Vancomycin-resistant enterococci (VREs) were
first isolated from patients in 1988 in the United King-
dom and France [3]. Since then, VRE have spread to many
other countries including Malaysia, in the meat from live-
stock and by humans [4-7].
Vancomycin resistance in Enterococci have been classified
based on the gene sequence and resistance characteristics
[8]. The vanA-type strains are resistant to high levels of
both vancomycin and teicoplanin antimicrobials (MIC ≥
64 µg/ml and >16 µg/ml, respectively). vanB-type strains
are resistant to a wide range of vancomycin concentration
(MIC between 4 to ≥ 1,024 µg/ml) and are susceptible to
teicoplanin. vanD-type strains are resistant to moderate
levels of vancomycin (MIC 128 µg/mL) and susceptible to
teicoplanin, while vanC,  vanE, and vanG-type strains
exhibit low-level resistance to vancomycin [3,9]. High
level gentamicin resistance (HLGR) phenotype is due to
the expression of bifunctional aminoglycoside-modifying
enzymes [AAC(6')-APH(2")] that are encoded by the
aacA-aphD gene (Gentamicin MICs range, ≥ 100–500 µg/
ml) [10,11].
Enterococcal infections are treated with ampicillin only or
with a combination of ampicillin and aminoglycoside to
achieve synergistic bactericidal activity. However, for
patients who are allergic to penicillin or are infected by
bacteria with high resistance to ampicillin and aminogly-
cosides, vancomycin is the powerful, last resort and alter-
native drug of choice. Intrinsic low-level resistance to
aminoglycosides is an inherent property of enterococci.
However, the prevalence of high level gentamicin resist-
ance in enterococci is predictive of a loss of synergy
between gentamicin and cell wall active agent such as
ampicillin or vancomycin [3].
Nucleic acid-based tests using PCR are increasingly being
used in laboratories to replace time-consuming, labor-
intensive and less sensitive conventional diagnostic meth-
ods such as biochemical identification and Kirby-Bauer
antimicrobial susceptibility tests. Various PCR methods
have been developed to identify the (i) Enterococcus genus
[12], (ii) vancomycin resistance [13], and (iii) high level
aminoglycoside resistance [14]. The above methods do
not detect all of the above mentioned targets simultane-
ously. Hence, the present study was focused to design a
nanoplex PCR of vancomycin and bifunctional aminogly-
coside resistant enterococci (V-BiA-RE) with an internal
control for the detection of (i) Enterococcus genus and clin-
ically important Enterococcus spp., namely E. faecalis and
E. faecium, (ii) most common vancomycin resistant geno-
types namely vanA, B, C, D and (iii) high level gentamicin
resistance. In order to rule out false negative results, an
internal control was also included in the nanoplex PCR
assay.
Results
In the present study the V-BiA-RE nanoplex PCR was opti-
mized successfully to identify 8 genes of Enterococcus
genus, species (E. faecalis and E. faecium), vancomycin
resistance (vanA, vanB, vanC and vanD) and high level
gentamicin resistance (aacA-aphD) simultaneously. Step-
wise optimization of primer concentration, annealing
temperature, MgCl2, dNTP and Taq polymerase was done.
The V-BiA-RE nanoplex PCR gave the best results when 4
mM MgCl2, 300 µM dNTP, 2 U Taq polymerase and 65°C
annealing temperature was used.
The analytical sensitivity of the nanoplex PCR at the DNA
level was found to be 1 ng of DNA (data not shown),
whereas at the bacterial level it was found to be 105 CFU/
mL (data not shown).
The analytical specificity of the nanoplex PCR assay at the
genus level was determined using 13 enterococcal refer-
ence strains and found to be positive for the Enterococcus
genus specific 16S rRNA gene. A representative gel picture
of V-BiA-RE with reference strains is shown in Figure 1,
while the other 10 Gram-positive and 20 Gram-negative
strains were negative. At the species level, all the reference
strains of E. faecalis and E. faecium were positive for ddl
gene by nanoplex PCR, while other Enterococcus species
were negative (Table 1). The vancomycin and gentamicin
resistant reference strains were positive for vanA, vanB,
vanC, vanD or aacA-aphD genes by nanoplex PCR. How-
ever, the vancomycin and gentamicin sensitive reference
strains were negative for vanA, vanB, vanC, vanD or aacA-
aphD genes by nanoplex PCR (Table 1). Overall, the ana-
lytical specificity of nanoplex PCR was 100% for the detec-
tion of vancomycin and gentamicin resistant reference
strains.
The DNA sequencing results of the PCR amplicon for the
8 genes were contig aligned using the ContigExpress alig-
ment program and were analyzed by BLAST. The results
showed that all 8 PCR amplicons were specific to their
respective genes and had 91–100% sequence identity with
the existing Genbank sequences.BMC Microbiology 2007, 7:112 http://www.biomedcentral.com/1471-2180/7/112
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Upon completion of the standardization of the V-BiA-RE
nanoplex PCR with reference strains, the assay was vali-
dated with 159 clinical isolates. Among the 159 clinical
isolates 154 (97%) were found to be E. faecalis and only 5
(3%) were E. faecium. Of the five E. faecium isolates, four
were from blood samples and one was from urine sample.
Of the remaining 154 E. faecalis isolates, 34 were from
blood samples, 59 from urine samples, 42 from pus sam-
ples, 6 from high vaginal swab samples, 10 from body
fluid samples, 1 from a peritoneum dialysis fluid sample
and 2 from urine catheter samples. Thus, the clinical iso-
lates had a high percentage of E. faecalis infections. How-
ever, none of the clinical Enterococcus  isolates showed
vancomycin resistance.
Among the 159 enterococci isolates, 42 had aacA-aphD
gene by V-BiA-Re nanoplex PCR. Of the 42 isolates, 39
were E. faecalis while 3 were E. faecium. However, by the
conventional antimicrobial susceptibility method 41 of
them were HLGR enterococci (Gentamicin MIC ≥ 100–
500 µg/mL). One of the E. faecium isolate that was posi-
tive for aacA-aphD gene by nanoplex PCR was found to be
Table 1: Bacterial species and strains used in this study and results of V-BiA-RE nanoplex PCR.
No. Reference strains 16S rRNAa ddl-E. faecalis ddl-E. faecium vanA vanB vanC vanD aacA-aphDb Internal control
1. E. faecium LMG 16004c +- + + - - - - +
2. E. durans LMG 16172c +- - + - - - - +
3. E. faecium LMG 16192c +- + + - - - - +
4. E. faecalis LMG 8222c + + - ---- - +
5. E. faecalis LMG 17122c + + - ---- - +
6. E. faecalis LMG 16216c ++ - - + - - + +
7. E. faecium LMG 16200c + - + ---- - +
8. E. raffinosus LMG 12172c + - - ---- - +
9. E. mundti LMG 12308c + - - ---- - +
10. E. hirae LMG 6399c + - - ---- - +
11. E. avium, LMG 10744c + - - ---- - +
12. E. faecium BM 4339 d + - + ---+ + +
13. E. casseliflavuse +- - - - + - - +
14. S. aureusf - - - ---- - +
15. Streptococcus spp. Group Af - - - ---- - +
16. Streptococcus spp. Group Bf - - - ---- - +
17. Streptococcus spp. Group Gf - - - ---- - +
18. Streptococcus spp. Group Ff - - - ---- - +
19. Bacillus spp.f - - - ---- - +
20. Listeria spp.f - - - ---- - +
21. Corynebacterium spp.f - - - ---- - +
22. Gardnerella spp.f - - - ---- - +
23. Lactobacillus spp.f - - - ---- - +
24. E. coli (EHEC)f -- - - + - - - +
25. E. coli (EPEC)f - - - ---- - +
26. E. coli (ETEC)f -- - - + - - - +
27. V. cholerae (O1 classical)f - - - ---- - +
28. V. cholerae O139 f - - - ---- - +
29. V. mimicusf - - - ---- - +
30. V. cincinnatiensisf - - - ---- - +
31. V. furnissiif - - - ---- - +
32. V. parahaemolyticusf - - - ---- - +
33. S. typhif - - - ---- - +
34. S. sonneif - - - ---- - +
35. S. entericaf - - - ---- - +
36. S. dysenteriaef - - - ---- - +
37. S. boydiif - - - ---- - +
38. C. freundiif - - - ---- - +
39. Y. enterocoliticaf - - - ---- - +
40. P. mirabilisf - - - ---- - +
41. P. aeruginosaf - - - ---- - +
42. K. pneumoniaef - - - ---- - +
43. P. Shigelloidesf - - - ---- - +
aEnterococcus genus
b Bifunctional aminoglycoside resistant genotype
c Reference strains from Belgian Co-ordinated Collections of Micro-organisms (BCCM), Ghent, Belgium
d Kindly provided by Professor. Patrice Courvalin and Dr. Bruno Perichon, Institut Pasteur, Paris, France
e Obtained from Institute for Medical Research, Malaysia
f Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia. '+' is positive; '-' is negative by V-BiA-
RE PCRBMC Microbiology 2007, 7:112 http://www.biomedcentral.com/1471-2180/7/112
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sensitive to gentamicin by conventional MIC method.
Though genotypically the aacA-aphD gene was detected
and confirmed by PCR and sequencing, it is possible that
the aacA-aphD gene is non-functional and is not expressed
phenotypically or due to the presence of pseudogene [15].
The diagnostic accuracy of V-BiA-RE nanoplex PCR at the
genus and species level was determined using 159 clinical
isolates and found to have 100% sensitivity, specificity,
positive and negative predictive values. However, the V-
BiA-RE nanoplex PCR for the aacA-aphD gene detection
showed 97.7% sensitivity, 100% specificity, 100% posi-
tive and 99.4% negative predictive values in detecting
HLGR enterococci.
Discussion
The present study is unique since it is the first study where
we have developed a combined molecular test for the
determination of the Enterococcus  genus, two clinically
important species (E. faecalis and E. faecium) and vanA-D
genotypes and high level gentamicin resistance (HLGR)
simultaneously. Currently the available assay is able to
detect either gentamicin or vancomycin resistance [10-
13]. Though there are numerous reports on PCR assays for
the detection of VREs [13,16], only few of them have
incorporated internal controls in their assays to rule out
false negatives [17,18]. According to CLSI guidelines for
Molecular Diagnostic Methods for Infectious Diseases
(MM3-A2), incorporation of an internal control in the
reaction is essential for the diagnostic test to exclude false
negative result or the presence of inhibitors [19]. In the
present study, the inclusion of the 300 bp internal control
in the V-BiA-RE nanoplex PCR assay helped us to rule out
false negatives or PCR inhibitors.
The V-BiA-RE nanoplex PCR was found to be 100% sensi-
tive and specific in detecting known vancomycin and gen-
tamicin resistance genes in Enterococcal strains. The use
of V-BiA-RE PCR as a diagnostic tool was also studied by
analyzing 159 clinical isolates obtained from 3 different
hospitals in Malaysia. We found that most of them were
E. faecalis (94%) and all of them were susceptible to van-
comycin. However, 26% were resistant to HLGR. These
results are consistent with results of other groups, where
they have shown that E. faecalis is predominant among
the clinical isolates and were vancomycin sensitive
though some were HLGR enterococci [3,14].
In Malaysia the presence of VREs has been reported from
clinical [5-7] and farm animal samples [16,20]. Sporadic
cases of VRE infection and colonization have also been
reported in the neighboring country, Singapore [4]. Since
antimicrobial-resistant enterococci have been detected in
livestock in Malaysia, there could be a possible epidemio-
V-BiA-RE nanoplex PCR assay profile with reference strains Figure 1
V-BiA-RE nanoplex PCR assay profile with reference strains. M, 100 bp plus marker; Lane 1, LMG 17122 (16S rRNA and ddl-E. 
faecalis); lane 2, LMG 8222 (16S rRNA and ddl-E. faecalis); lane 3, LMG 16216 (16S rRNA, ddl-E. faecalis, vanB and aacA-aphD); 
lane 4, LMG 16004 (16S rRNA, ddl-E. faecium and vanA); lane 5, LMG 16200 (16S rRNA and ddl-E. faecium); lane 6, LMG 16192 
(16S rRNA, ddl-E. faecium and vanA); lane 7, BM 4339 (16S rRNA, ddl-E. faecium, vanD and aacA-aphD); lane 8, LMG 16172 E. 
durans (16S rRNA and vanA); lane 9, E. casseliflavus (16S rRNA and vanC); lane 10, LMG 12172 E. raffinosus (16S rRNA); lane 
11, LMG 12308 E. mundti (16S rRNA); lane 12, LMG 6399 E. hirae (16S rRNA); lane 13, LMG 10744 E. avium (16S rRNA); lane 
14, positive control and lane 15, negative control.BMC Microbiology 2007, 7:112 http://www.biomedcentral.com/1471-2180/7/112
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logical link between livestock origin and human infec-
tions [4-7,16,20]. Hence, characterization of VRE isolates
from human stools and livestock animals is needed, espe-
cially in areas where antibiotics can be obtained from any
drug store or over-the-counter and where farmers feed
their chickens with antibiotics to promote growth [3,15].
The percentage of HLGR enterococci observed in this
study (26%) is relatively lower than those reported in
China (64%) [10] and Greece (42%) [11]. In both studies,
the HLGR enterococci were mostly associated with the
presence of aacA-aphD gene as observed in this study.
Genomic DNA extracted from two of the E. coli (EHEC
and ETEC) strains found to have vanB gene like products
(Table 1). It has been documented that the E. coli possess
homologous genes called ddlA and ddlB [GenBank acces-
sion: U00096] that have 29–38% amino acid identity to
vanA and vanC genes [21]. However sequencing of these
PCR product revealed that it is similar to a hypothetical
protein present in E. coli (Gene-Ecs5269, GenBank acces-
sion number BA000007) and is not related to ddlA/ddlB
genes of E. coli. It is possible that in the nanoplex PCR
assay, the presence of 9 pairs of primers might have lead
to non-specific PCR product. These types of false positive
results do not arise when Enterococci broth is used as an
enrichment medium, since this medium is known to
inhibit Gram-negative bacterial (E. coli) growth.
The limitations of the conventional antimicrobial suscep-
tibility tests are that the susceptibility pattern varies with
inoculum size. In addition, there is no standardized MIC
cut-off value available for vanA, vanB, vanC1/C2/C3 and
vanD in conventional antimicrobial susceptibility tests.
Currently, it is not a usual practice in laboratories to iden-
tify the species of Enterococcus, except in cases of septi-
cemia. Genotype-based molecular tests can overcome the
limitation, where the presence of the gene is accurately
detected when the CFUs of the bacteria are more than the
analytical sensitivity level. Moreover, rapid detection of
antibiotic resistant bacteria is important not only for ther-
apeutic decisions, but also for infection control [15].
The vanE and vanG primers were not included in the V-
BiA-RE nanoplex PCR since these genotypes are not com-
mon among Enterococcus spp. [22]. The V-BiA-RE nano-
plex PCR assay developed in the present study will be
useful in the epidemiological screening of VRE carriers or
reservoirs. We are currently evaluating this assay for
screening VRE carriage in human stools and poultry farms
in Malaysia.
Conclusion
Bacterial lysates prepared by a simple boiling method
without lysis buffer and lytic enzymes were used as tem-
plates in the V-BiA-RE nanoplex PCR assay. The PCR assay
was able to detect 8 genes that are essential for the identi-
fication of the most common enterococci spp. and their
vancomycin and gentamicin resistance genotypes simulta-
neously in a single test within 4 hours. The built-in inter-
nal control in this assay prevents the false negative cases.
The diagnostic accuracy was determined using the 159
clinical specimens which showed 97% of the clinical iso-
lates belonged to E. faecalis, of which 26% showed HLGR
genotype, but none were vancomycin resistant. Hence,
this test can be used as an effective diagnostic and surveil-
lance tool to monitor the spread and emergence of VRE.
Methods
Study design
This is a retrospective diagnostic study where the sample
size was calculated by single proportion test based on the
prevalence of 12.3% [23] and 95% Confidence Interval
with expected specificity of 92%. The study was approved
by the Research and Ethics Committee, School of Medical
Sciences, Universiti Sains Malaysia.
Bacterial strains and clinical specimens
The reference Enterococcus spp. and other bacteria used in
this study are listed in Table 1. A total of 159 Enterococcus
spp. isolated from routine clinical specimens obtained
from three hospitals namely, Hospital Universiti Sains
Malaysia (HUSM), General Hospital Kota Bharu (GHKB)
and Hospital Tengku Ampuan Afzan, Kuantan, Malaysia
from May to October 2004 were used in this study. Of
these 159 isolates, 38 were isolated from blood samples,
60 from urine samples, 42 from pus samples, 6 from high
vaginal swabs, 10 from body fluid samples, 1 from perito-
neum dialysis fluid and 2 from urine catheter samples.
Screening of Enterococcus spp. from clinical specimens by 
conventional method
The clinical isolates were inoculated into Enterococci
broth (Merck, Darmstadt, Germany) and Enterococcosel
agar [Becton Dickinson (BD), BBL, New Jersey, USA] with-
out the addition of vancomycin and incubated at 37°C for
24 hours. The isolates that showed growth in both media
were selected for biochemical identification and antimi-
crobial susceptibility testing.
To differentiate Enterococcus from other Group D strepto-
cocci, isolated colonies from clinical specimens were
tested by standard biochemical tests (PYR: Oxoid, United
Kingdom, England; Enterococcosel agar: BD, BBL, New
Jersey, USA and 6.5% NaCl brain heart infusion (BHI)
broth: Oxoid, United Kingdom, England). Further confir-
mation to the species level was carried out as described by
Facklam and Waitkins [24,25]. The reference strains E.
raffinosus (LMG 12172) and E. durans (LMG16172) (Bel-
gian Co-ordinated Collections of Micro-organisms,BMC Microbiology 2007, 7:112 http://www.biomedcentral.com/1471-2180/7/112
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BCCM, Ghent, Belgium) were used as controls for the
above biochemical tests.
Minimum inhibitory concentration (MIC) of vancomycin
(CheilJedang, Korea), teicoplanin (Gruppo Lepetit, Italy)
and gentamicin (Duopharma, Malaysia) was determined
by agar dilution method according to CLSI (Clinical and
Laboratory Standards Institute) guidelines with slight
modification based on the procedures as described by
Hayes  et al.[26]. Furthermore, E-test kits (AB Biodisk,
Solna, Sweden) were also used to determine the suscepti-
bility patterns of vancomycin. The results were catego-
rized according to CLSI standards. Reference strains used
as controls were E. faecium (LMG 16192), E. faecalis (LMG
16216), E. faecium (BM 4339) and E. casseliflavus (Table
1).
Primer designing for V-BiA-RE nanoplex PCR
The 16S rRNA of Enterococcus genus, ddl of E. faecium, ddl
of E. faecalis, vanA, vanB, vanC, vanD, and aacA-aphD gene
sequences were obtained from GenBank [27] for DNA
sequence alignment and primer design. The ClustalW pro-
gram in Vector NTI version 9.0 software (Invitrogen Cor-
poration, California, USA) was used to align the DNA
sequences. The conserved and non-conserved regions of
the DNA sequence alignments were visualized using
GeneDoc software [28]. Based on the conserved regions of
the alignment, specific primer pairs were designed to
amplify the Enterococcus genus. Specific primers of E. fae-
cium and E. faecalis species were designed based on the
non-conserved regions of ddl gene sequences. Vancomy-
cin resistance specific primers were designed based on the
non-conserved regions of vanA,  vanB,  vanC, and vanD
DNA sequences. High level gentamicin resistance (HLGR)
specific primers were designed based on aacA-aphD gene.
The 8 primer pairs were designed in such a way that the
PCR products ranged from 150 bp to 1200 bp. The specif-
icity of the designed primers was checked using BLAST
available at the GenBank website [29]. The primer
sequences for the 8 genes and expected PCR product sizes
are shown in Table 2. A primer pair based on ctxA gene
was designed and was used as an internal control.
V-BiA-RE nanoplex PCR assay
The monoplex PCR for each gene and the V-BiA-RE nano-
plex PCR assays were standardized using genomic DNA
extracted from reference Enterococcus  spp. A mixture of
DNAs from 4 reference strains namely E. faecium (LMG
16192), E. faecalis (LMG 16216), E. faecium (BM 4339)
and E. casseliflavus that contained the 8 genes of interest
was used as a positive control. DNase-free distilled water
was used as a negative control. In addition, a plasmid con-
taining ctxA gene (1 pg) was used as a template for the
internal control. To rule out false negative activities, an
internal control (primers pair and template) was incorpo-
rated in every reaction mixture including negative con-
trols.
The diagnostic evaluation of the nanoplex PCR was done
using the lysates from 159 clinical isolates. The isolated
colonies from Enterococcosel agar were inoculated into
LB broth and incubated at 37°C for 24 hours. Bacterial
lysates for PCR were prepared by centrifuging the 100 µl
of culture at 10,000 × g for 3 minutes, the supernatant
were removed and the pellets were resuspended in 100 µl
of DNase-free distilled water. The suspensions were
Table 2: Sequences of primers used for the V-BiA-RE nanoplex PCR.
Gene Primer Name 5'--------------------------------3' GenBank Accession Number Product Size
16S rRNA 16SrRNA-F AGG GGA TAA CAC TTG GAA ACA AB015233 1178 bp
16SrRNA-R TTC GCG ACT CGT TG TAC TTC
ddl E. faecalis Elis-F2 GGC CCT CTT TTA TCT GAA CGA U00457 734 bp
Elis-R3 GCG ACT TAA GCC ACT TCC AT
ddl E. faecium Ecium-F CGC AGA GCA TGA AGT GTC CA AF550665 557 bp
Ecium-R2 CTT CTC GGT TTT CTG CTT TTG TA
VanA vanA-F TTG GGG GTT GCT CAG AGG AG X56895 931 bp
vanA-R CTT CGT TCA GTA CAA TGC GG
VanB vanB-F AAT GCG GGG AGG ATG GTG CG AF550667 446 bp
vanB-R GAT GCG GAA GAT ACC GTG GC
VanC vanC-F2 GCA GGT TCT GCC TTA TGT ATG AA AF162694, AY033764, L29638 339 bp
vanC-R ATG AAA TGG CGT CAC AAG CA
VanD vanD-F CGT ATG TGG GAT GCG ATA TTC AA AF130997 230 bp
vanD-R2 CTT CGA TTG CTG CCT GCA GTT
aacA-aphD acph-F1L GAT TTG CCA GAA CAT GAA TTA CAC GA AY602207 156 bp
acph-R1L CAT AAC CAC TAC CGA TTA TTT CAA T
Internal Control (ctxA) IC-F AAC TCA GAC GGG ATT TGT TAG GC AF510996 300 bp
IC-R TCT CTG TAG CCC CTA TTA CGA TGTBMC Microbiology 2007, 7:112 http://www.biomedcentral.com/1471-2180/7/112
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boiled in a water bath for 10 minutes and centrifuged
again at 10,000 × g for 3 minutes. Then, 2 µl of the super-
natants (lysates) were used in the V-BiA-RE nanoplex PCR
assays.
The optimized concentration of primer for each gene (0.2
pmol 16S rRNA, 0.8 pmol ddl-E. faecium, 0.8 pmol ddl-E.
faecalis, 0.8 pmol vanA, 0.05 pmol vanB, 0.7 pmol vanC,
0.4 pmol vanD, 1 pmol aacA-aphD and 0.2 pmol ctxA) was
used in the V-BiA-RE nanoplex PCR. The other compo-
nents used in the PCR were 300 µM dNTPs, 4 mM MgCl2,
1× PCR buffer and 2 U Taq DNA polymerase (Fermentas,
Vilnius, Lithuania). The PCR was carried out using a Mas-
tercycler Gradient (Eppendorf, Hamburg, Germany) with
one cycle of initial denaturation at 95°C for 5 min, 30
cycles of denaturation at 95°C for 30 sec, annealing for 30
sec at 65°C and extension at 72°C for 30 sec, followed by
an extra cycle of annealing at 65°C for 30 sec and a final
extension at 72°C for 5 min. The PCR products were ana-
lyzed by electrophoresis on 2% low EEO agarose gels
(Promega, Madison, USA) with ethidium bromide at 90
Volts for 75–90 min. PCR products were visualized under
UV illumination and photographed using an image ana-
lyzer (ChemiImager 5500, Alpha Innotech, California,
USA).
Confirmation of the PCR amplicons by DNA sequencing
All eight PCR products of the different genes that were
obtained from reference strains (Table 1) were cloned into
a PCR cloning vector pTZ57T/R (Fermentas, Vilnius,
Lithuania) and sequenced using an automated DNA
sequencer at Tech Dragon Ltd (Hong Kong, China). The
DNA sequencing results were analyzed using the Con-
tigExpress alignment program in Vector NTI version 9.0
software (Invitrogen corporation, California, USA).
Resultant contigs were analyzed by BLAST [29] provided
by the National Center for Biotechnology Information to
calculate the percentage identity.
Evaluation of V-BiA-RE nanoplex PCR assay
Analytical specificity was evaluated using DNA lysates pre-
pared from pure cultures of 13 phenotypically and geno-
typically well-characterized Enterococcus  spp. and 10
Gram-positive and 20 Gram-negative strains obtained
from different sources (Table 1).
The analytical sensitivity was evaluated using various con-
centrations of genomic DNA starting from 1 µg to 10 pg
and lysate starting from 108 – 103 CFU/ml obtained from
a reference strain, E. faecalis (LMG 16216).
The diagnostic evaluation of the nanoplex PCR was car-
ried out using 159 clinical isolates. The results were com-
pared with the conventional microbiological,
biochemical, and antimicrobial susceptibility tests which
were considered as the 'gold standard' [30].
Statistical analysis
The clinical sensitivity, specificity, positive (PV+) and neg-
ative predictive value (PV-) of V-BiA-RE nanoplex PCR
were calculated based on the CLSI Guidelines for Molecu-
lar Diagnostic Methods for Infectious Diseases [30].
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